(Total Views: 388)
Posted On: 04/27/2020 7:00:19 PM
Post# of 36566
Thank you so much RJS!
Does anyone have any guesses as to when GNBT can capitalize on this?
RJS wrote -
New peer review
“In a post hoc analysis of patients with both advanced stage and HER2 under-expression there was a significant improvement in DFS favoring the vaccine group (AE37 83.0% vs Control 62.5%, p = 0.039, HR 0.375 CI 0.142–0.988, Fig. 5f). There was a similar trend towards clinical benefit in patients with both advanced stage disease and TNBC (AE37 85.7% vs Control 36.4%, p = 0.078, HR 0.184 CI 0.022–1.510, Fig. 5g).“
We basically knew this, but peer review always strengthens the science.
https://link.springer.com/article/10.1007/s10549-020-05638-x
Read More: https://investorshangout.com/post/newpost/622...z6KrBCkYuI
Does anyone have any guesses as to when GNBT can capitalize on this?
RJS wrote -
New peer review
“In a post hoc analysis of patients with both advanced stage and HER2 under-expression there was a significant improvement in DFS favoring the vaccine group (AE37 83.0% vs Control 62.5%, p = 0.039, HR 0.375 CI 0.142–0.988, Fig. 5f). There was a similar trend towards clinical benefit in patients with both advanced stage disease and TNBC (AE37 85.7% vs Control 36.4%, p = 0.078, HR 0.184 CI 0.022–1.510, Fig. 5g).“
We basically knew this, but peer review always strengthens the science.
https://link.springer.com/article/10.1007/s10549-020-05638-x
Read More: https://investorshangout.com/post/newpost/622...z6KrBCkYuI
(0)
(0)
